http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Soligenix (SNGX) Enters Agreement with EMA on Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte
-
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
-
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
-
Soligenix, Inc. (SNGX) Forms Behçet's Disease Medical Advisory Board
-
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
-
Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Soligenix to Present at The Microcap Conference
-
Soligenix, Inc. (SNGX)Announces FDA Grants "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
-
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
-
Soligenix (SNGX) Reports Top-line Results of the Phase 2a Study of SGX302
-
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
-
Soligenix (SNGX) Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
-
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
-
"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery
-
Soligenix (SNGX) Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
-
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
-
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
-
Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results
-
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
-
ASP Isotopes and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
-
Soligenix to Present at The ThinkEquity Conference
-
SPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
-
Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
-
Soligenix, Inc. (SNGX) Achieves Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures
-
Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures
-
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders
-
Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results
-
BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
-
HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
-
Soligenix (SNGX) Announces Expansion of SGX302 Phase 2a Study
-
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis
-
Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
-
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis
-
Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results
-
Soligenix, Inc. (SNGX) Announces Scheduling of Type A Meeting with FDA to Review Study Design for a Second Phase 3 Study of HyBryte
-
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix, Inc. (SNGX) Reports Positive Clinical Results from Compatibility Study of HyBryte
-
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix (SNGX) Enters Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease
-
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease
-
Soligenix, Inc. (SNGX) Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix (SNGX) Provides Regulatory Update on HyBryte
-
Soligenix Provides Regulatory Update on HyBryte™
-
Soligenix (SNGX) Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302
-
Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302
-
Soligenix (SNGX) Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte New Drug Application
-
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results
-
Soligenix (SNGX) Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
